Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker VTRS · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | A Phase 1/2, Single-Dose, Multicenter, Dose Escalation, Clinical Trial to Evaluate the Safety and E… NCT07923045 · Neurotrophic Keratopathy MR-146 | VTRS Viatris Inc. | Phase 1/2 | Recruiting | 18 | Nov 30, 2027 | Registry ↗ |
| Nov 3, 2026 | Dymista in Chinese Adolescents NCT07597473 · Allergic Rhinitis Due to Allergens Treatment with 137 µg azelastine hydrochloride and 50 μg of… | VTRS Viatris Inc. | Phase 4 | Completed was active, not recruiting | 100 | Sep 19, 2026 | Registry ↗ |
| Oct 30, 2026 | A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From System… NCT05672576 · Lupus Erythematosus, Systemic Cenerimod, Placebo | VTRS Viatris Innovation GmbH | Phase 3 | Active, not recruiting | 451 | Dec 31, 2026 | Registry ↗ |
| Oct 30, 2026 | A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Sys… NCT05648500 · Lupus Erythematosus, Systemic Cenerimod, Placebo | VTRS Viatris Innovation GmbH | Phase 3 | Active, not recruiting | 470 | Mar 31, 2027 | Registry ↗ |
| Oct 27, 2026 | A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults… NCT07615868 · Chronic Coronary Syndrome Selatogrel, Matching placebo | VTRS Viatris Innovation GmbH | Phase 1 | Completed | 20 | Sep 19, 2026 | Registry ↗ |
| Oct 27, 2026 | Selatogrel Outcome Study in Suspected Acute Myocardial Infarction NCT04957719 · Acute Myocardial Infarction Selatogrel, Placebo | VTRS Viatris Innovation GmbH | Phase 3 | Enrolling by invitation | 25,000 | Jul 2027 | Registry ↗ |
| Oct 15, 2026 | Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, N… NCT07813026 · Healthy Placebo, Oxycodone 20mg | VTRS Viatris Inc. | Phase 4 | Recruiting | 60 | Jan 31, 2027 | Registry ↗ |
| Oct 13, 2026 | Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbear… NCT06672016 · Female Contraception Transdermal system containing progestin | VTRS Mylan Pharmaceuticals Inc | Phase 3 | Active, not recruiting | 1,630 | May 2027 | Registry ↗ |
| Sep 14, 2026 | Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cyc… NCT05139121 · Contraception MR-100A-01 | VTRS Mylan Technologies Inc. | Phase 3 | Completed | 1,320 | Jan 15, 2025 | Registry ↗ |
| Sep 11, 2026 | Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus NCT06475742 · Lupus Erythematosus, Systemic Cenerimod | VTRS Viatris Innovation GmbH | Phase 3 | Enrolling by invitation | 680 | Sep 2032 | Registry ↗ |
| Sep 8, 2026 | Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sed… NCT07777965 · Healthy Non-dependent, Recreational Sedative Users Alprazolam (Xanax), Placebo | VTRS Viatris Inc. | Phase 4 | Completed | 44 | Aug 31, 2026 | Registry ↗ |
| Aug 3, 2026 | Extension Study of MYL-1701P-3001 for Safety and Efficacy NCT04674800 · Diabetic Macular Edema MYL-1701P, a proposed biosimilar to Eylea | VTRS Mylan Pharmaceuticals Inc | Phase 3 | Completed | 52 | Apr 20, 2022 | Registry ↗ |
| Jul 30, 2026 | A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on… NCT07201129 · Nephritis, Lupus, Lupus Erythematosus, Systemic Cenerimod, Placebo | VTRS Viatris Innovation GmbH | Phase 3 | Recruiting | 300 | Aug 2029 | Registry ↗ |
| Jul 29, 2026 | Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Sy… NCT03742037 · Systemic Lupus Erythematosus Cenerimod 0.5 mg, Cenerimod 1 mg | VTRS Viatris Innovation GmbH | Phase 2 | Completed | 427 | Aug 31, 2021 | Registry ↗ |
| Jul 29, 2026 | A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack NCT03487445 · Acute Myocardial Infarction Selatogrel 8 mg, Selatogrel 16 mg | VTRS Viatris Innovation GmbH | Phase 2 | Completed | 48 | Nov 10, 2018 | Registry ↗ |
| Jul 29, 2026 | A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disea… NCT03384966 · Stable Coronary Artery Disease Selatogrel, Placebo | VTRS Viatris Innovation GmbH | Phase 2 | Completed | 346 | Aug 18, 2018 | Registry ↗ |
| Jul 29, 2026 | Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics o… NCT02472795 · Systemic Lupus Erythematosus Matching placebo, Cenerimod | VTRS Viatris Innovation GmbH | Phase 1/2 | Completed | 105 | Jan 23, 2017 | Registry ↗ |
| Jul 28, 2026 | A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in A… NCT07266090 · SLE - Systemic Lupus Erythematosus cenerimod 4 mg | VTRS Viatris Pharmaceuticals Co., Ltd. | Phase 2 | Active, not recruiting | 15 | Oct 8, 2027 | Registry ↗ |
| Jul 14, 2026 | A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Participants NCT07301723 · Healthy Subjects Cenerimod (oral), 14C-Cenerimod (i.v.) | VTRS Viatris Innovation GmbH | Phase 1 | Completed | 6 | Mar 18, 2026 | Registry ↗ |
| Jul 14, 2026 | A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Ca… NCT07133191 · Healthy Volunteers Selatogrel, Matching placebo | VTRS Viatris Innovation GmbH | Phase 1 | Completed | 32 | Nov 5, 2025 | Registry ↗ |
| Feb 10, 2026 | Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy NCT06215859 · Acute Pain, Post Operative Pain MR-107A-02, Tramadol | VTRS Viatris Specialty LLC | Phase 3 | Completed | 579 | Jan 31, 2025 | Registry ↗ |
| Jan 26, 2026 | Investigating Ovulation Inhibition for Use as a Contraceptive NCT07365904 · Contraception MR-130A-01 contraceptive transdermal patch, containing nore… | VTRS Mylan Pharmaceuticals Inc | Phase 2 | Recruiting | 60 | Nov 30, 2026 | Registry ↗ |
| Oct 14, 2025 | Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy NCT06215820 · Acute Pain, Post Operative Pain MR-107A-02, Tramadol | VTRS Viatris Specialty LLC | Phase 3 | Completed | 410 | Aug 24, 2024 | Registry ↗ |
| Sep 30, 2025 | Study to Evaluate the Effectiveness of Legalon® NCT05051527 · Non-alcoholic Fatty Liver Disease (NAFLD) Legalon® 140 mg | VTRS Mylan Inc. | — | Completed | 362 | Oct 31, 2024 | Registry ↗ |
| Sep 22, 2025 | The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics NCT05004311 · Healthy, Renal Impairment Cenerimod | VTRS Viatris Innovation GmbH | Phase 1 | Completed | 16 | Jul 27, 2023 | Registry ↗ |
| Sep 22, 2025 | A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of… NCT04819464 · Healthy, Hepatic Impairment Cenerimod | VTRS Viatris Innovation GmbH | Phase 1 | Completed | 24 | Aug 18, 2024 | Registry ↗ |
| Sep 22, 2025 | To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Stud… NCT04255277 · Healthy Subjects Combined oral contraceptives (COC), Moxifloxacin 400mg | VTRS Viatris Innovation GmbH | Phase 1 | Completed | 97 | Sep 14, 2021 | Registry ↗ |
| Sep 22, 2025 | Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects NCT04052360 · Healthy Volunteers Cenerimod, Matching Placebo | VTRS Viatris Innovation GmbH | Phase 1 | Completed | 20 | Oct 29, 2019 | Registry ↗ |
| Sep 22, 2025 | A Study to Evaluate Cenerimod in Healthy Male Subjects NCT02914223 · Healthy Subjects Cenerimod | VTRS Viatris Innovation GmbH | Phase 1 | Completed | 6 | Dec 1, 2016 | Registry ↗ |
| Sep 22, 2025 | Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic… NCT02479204 · Healthy Subjects ACT-334441 2 mg, ACT-334441 4 mg | VTRS Viatris Innovation GmbH | Phase 1 | Terminated | 10 | May 1, 2016 | Registry ↗ |
| Jul 4, 2025 | The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics NCT04406896 · Healthy Subjects, Hepatic Impairment Selatogrel | VTRS Viatris Innovation GmbH | Phase 1 | Completed | 24 | Oct 23, 2020 | Registry ↗ |
| Jul 3, 2025 | A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects NCT04557280 · Healthy Subjects Selatogrel, Selatogrel | VTRS Viatris Innovation GmbH | Phase 1 | Completed | 24 | Dec 19, 2020 | Registry ↗ |
| Jul 3, 2025 | A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Health… NCT03814200 · Healthy Subject Saline, ACT-246475 | VTRS Viatris Innovation GmbH | Phase 1 | Completed | 14 | Feb 12, 2019 | Registry ↗ |
| Jul 3, 2025 | A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects NCT03593278 · Healthy Subjects ACT-246475 | VTRS Viatris Innovation GmbH | Phase 1 | Completed | 6 | Aug 5, 2018 | Registry ↗ |
| Jul 3, 2025 | A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelo… NCT03430661 · Healthy ACT-246475, Clopidogrel | VTRS Viatris Innovation GmbH | Phase 1 | Completed | 77 | May 20, 2019 | Registry ↗ |
| Jul 2, 2025 | A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its… NCT03173625 · Healthy Subjects AC-076 for s.c. administration, Placebo | VTRS Viatris Innovation GmbH | Phase 1 | Completed | 72 | Apr 15, 2017 | Registry ↗ |
| Nov 29, 2024 | Dose-finding Study of MR-130A-01 Contraceptive Transdermal Patch NCT06048536 · Contraception MR-130A-01 Transdermal patch, MR-130A-01 Transdermal patch | VTRS Mylan Pharmaceuticals Inc | Phase 2 | Completed | 168 | Jan 18, 2024 | Registry ↗ |
| Nov 1, 2024 | Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(… NCT05046795 · COPD Revefenacin 175 mcg in 3 ML Inhalation Solution, Placebo in… | VTRS Mylan Pharma UK Ltd. | Phase 3 | Completed | 258 | Jul 26, 2023 | Registry ↗ |
| Jul 24, 2024 | Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Partic… NCT04570436 · Abuse Potential gabapentin 600 mg, gabapentin 1200 mg | VTRS Viatris Specialty LLC | Phase 4 | Completed | 52 | Nov 10, 2022 | Registry ↗ |
| Jun 24, 2024 | Safety and Efficacy Evaluation of <Dovprela Tablets 200 mg> by Post-marketing Surveillance NCT06471088 · Dovprela Dovprela | VTRS Viatris Inc. | — | Unknown | 100 | Jun 30, 2026 | Registry ↗ |
| Apr 24, 2024 | Food Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg NCT00650533 · Healthy Glimepiride Tablets 1 mg, Amaryl® Tablets 1 mg | VTRS Mylan Pharmaceuticals Inc | Phase 1 | Completed | 40 | Dec 2004 | Registry ↗ |
| Apr 24, 2024 | Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets NCT00650520 · Healthy BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg, Parlodel® (bromo… | VTRS Mylan Pharmaceuticals Inc | Phase 1 | Completed | 119 | Jul 2007 | Registry ↗ |
| Apr 24, 2024 | Fasting Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg NCT00650481 · Healthy Oxybutynin Chloride Extended-release Tablets 5 mg, Ditropan… | VTRS Mylan Pharmaceuticals Inc | Phase 1 | Completed | 60 | Dec 2002 | Registry ↗ |
| Apr 24, 2024 | Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg NCT00650416 · Healthy Carvedilol Tablets 12.5 mg, Coreg® Tablets 12.5 mg | VTRS Mylan Pharmaceuticals Inc | Phase 1 | Completed | 50 | Apr 2004 | Registry ↗ |
| Apr 24, 2024 | Food Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg NCT00650403 · Healthy Paroxetine hydrochloride 40 mg tablet, Paxil® 40 mg Tablet | VTRS Mylan Pharmaceuticals Inc | Phase 1 | Completed | 66 | Dec 2006 | Registry ↗ |
| Apr 24, 2024 | Fasting Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg NCT00650364 · Healthy Midodrine HCl Tablets 5 mg, ProAmatine® Tablets 5 mg | VTRS Mylan Pharmaceuticals Inc | Phase 1 | Completed | 38 | Aug 2002 | Registry ↗ |
| Apr 24, 2024 | Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg NCT00650351 · Healthy Ciprofloxacin Extended-Release Tablets 1000 mg, Cipro® XR T… | VTRS Mylan Pharmaceuticals Inc | Phase 1 | Completed | 35 | Oct 2005 | Registry ↗ |
| Apr 24, 2024 | Study of Sertraline Hydrochloride Tablets 100 mg and Zoloft® Tablets 100 mg NCT00650325 · Healthy Sertraline Hydrochloride Tablets 100 mg, Zoloft® Tablets 10… | VTRS Mylan Pharmaceuticals Inc | Phase 1 | Completed | 49 | Dec 2002 | Registry ↗ |
| Apr 24, 2024 | Fasting Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg NCT00650312 · Healthy Metformin Hydrochloride ER Tablets 500 mg, Glucophage® XR T… | VTRS Mylan Pharmaceuticals Inc | Phase 1 | Completed | 50 | Oct 2002 | Registry ↗ |
| Apr 24, 2024 | Fed Study of Alprazolam Extended-release Tablets 3 mg to Xanax XR® Tablets 3 mg NCT00650299 · Healthy Alprazolam Extended-release Tablets 3 mg, Xanax XR® Tablets… | VTRS Mylan Pharmaceuticals Inc | Phase 1 | Completed | 21 | Aug 2004 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:26 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances